UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.

Pyxis Oncology, a US-based cancer therapy developer spun out of University of Chicago (UChicago), set the price range for its proposed IPO at $14 to $16 yesterday.

The spinout plans to issue 8.34 million shares on the Nasdaq Global Market to list under the ticker symbol PYXS. At the lower end, Pyxis would generate nearly $117m in proceeds, rising to more than $133m at the top end and as much as $153m including the greenshoe option.

Founded in 2018,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn